Trial Profile
A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study of the Safety and Tolerability of Intravenously Administered REGN846 (SAR302352) in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Apr 2014
Price :
$35
*
At a glance
- Drugs REGN 846 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Regeneron Pharmaceuticals
- 24 Apr 2014 New trial record